Ophthalmic technology developer Intalight has received the CE mark for its DREAM OCT [optical coherence tomography] platform, allowing the company to commercialise it within the European Union (EU).
Intalight noted that with its ultrawide field single scan, the platform provides a comprehensive 130° OCT angiography (OCTA) image.
Related: FDA clears Trax Surgical Linkt nitinol compression staple system
The device’s swept-source 12mm super-depth scanning offers visualisation of the choroid, retina, and a significant portion of the vitreous space.
Its anterior scanning capabilities also enable a complete view of the segment in a single scan, measuring 16.2mm in air.
Intalight’s DREAM OCT leverages ultra-wide swept-source technology to cater to the specific needs of retina specialists and ophthalmologists.
It has a scanning speed of up to 400KHz, essential for high-resolution OCTA, removing artefacts caused by eye movements.
The platform is also said to be capable of covering a field of 26mm × 21mm on the retina with a single scan, and an automatic montage can expand the range further to 200°, revealing lesions towards the retina’s edge.
According to the company, DREAM OCT can identify minute vascular pathologies, upholding a low false-positive rate.
Additional features such as 3D Projection Artefact Removal and Deep Layer algorithms minimise artefacts.
Intalight co-founder and CEO Bing Li said: “Over the past few years, we’ve heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy, and depth.
“DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCPs know.”
